Figure 6.

LIHC01714 Is a Candidate Therapeutic Target for CCA

(A) IC₅₀ analysis for gemcitabine-treated CCLP1 cells with si-LINC01714 and corresponding control transfection. (B) IC₅₀ analysis for gemcitabine-treated HuCCT1 cells with LINC01714 and corresponding control transfection. (C) LINC01714 suppressed the liver metastasis of CCA tumor in the nude mouse model bearing subcutaneous tumor xenografts from gemcitabine-treated CCLP1 cell lines. (D) Thermographic assessment of liver or lung tumor in LINC01714 overexpression and control mouse groups. (E) Representative data of H&E staining in the tumor foci of the liver or lung samples obtained from nude mice after injection with LINC01714-overexpression cells. (F) Survival analysis between mouse groups with gemcitabine-treated CCLP1 cell lines with LINC01714 or control transfection. (G) IC₅₀ analysis for gemcitabine-treated CCLP1 cells with siLINC01714+FOXO3 and corresponding control transfection (Student’s t test p < 0.001). (H) IC₅₀ analysis for gemcitabine-treated HuCCT1 cells with LINC0174+siFOXO3 and corresponding control mice groups (Student’s t test p = 0.0002). (I) Mechanism model depicting briefly how LINC01714 enhances gemcitabine sensitivity through reducing FOXO3 phosphorylation in CCA cells. Values are indicated as mean ± SEM in (C). **p < 0.01; ***p < 0.001.